A wide spectrum of skin toxicities has been described in patients receiving epidermal growth factor receptor (EGFR), inhibitors, including papulopustular rash, xerosis and fissures, pruritus, mucositis, paronychia, and hair changes.Trichomegaly of the eyelashes is a rare adverse effect of EGFR inhibitor therapy and is characterized by a paradoxical overgrowth of eyelashes. We present 3 cases of trichomegaly occurred during EGFR inhibitor therapy.
Get full access to this article
View all access options for this article.
References
1.
PeuvrelL, BachmeyerC, ReguiaiZ, et al.Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors. Support Care Cancer, 2012; 20 (5): 909-921.
2.
BalagulaY, GarbeC, MyskowskiPL, et al.Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol, 2011; 50: 129-146.
3.
AlexandrescuDT, KauffmanCL, DasanuCA. The cutaneous epidermal growth factor network: can it be translated clinically to stimulate hair growth?. Dermatol Online J, 2009; 15: 1.
4.
LacoutureME, AnadkatMJ, BensadounRJ, et al.MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer, 2011; 19: 1079-1095.
VergouT, StratigosAJ, KarapanagiotouEM, et al.Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol, 2010; 63 (2): e56-e58.
